Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OCS 
Oculis Holding AG Ordinary shares (OCS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: OCS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $42.72
1 Year Target Price $42.72
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 30.37% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.13B USD | Price to earnings Ratio - | 1Y Target Price 42.72 |
Price to earnings Ratio - | 1Y Target Price 42.72 | ||
Volume (30-day avg) 7 | Beta 0.13 | 52 Weeks Range 14.00 - 23.08 | Updated Date 10/30/2025 |
52 Weeks Range 14.00 - 23.08 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7957.09% |
Management Effectiveness
Return on Assets (TTM) -29.71% | Return on Equity (TTM) -83.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 714473585 | Price to Sales(TTM) 1476.22 |
Enterprise Value 714473585 | Price to Sales(TTM) 1476.22 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.47 | Shares Outstanding 52335759 | Shares Floating 41333736 |
Shares Outstanding 52335759 | Shares Floating 41333736 | ||
Percent Insiders 6.31 | Percent Institutions 31.39 |
Upturn AI SWOT
Oculis Holding AG Ordinary shares
Company Overview
History and Background
Oculis Holding AG is a biopharmaceutical company focusing on developing ophthalmic treatments. Founded relatively recently, it is dedicated to innovation in addressing unmet needs in eye care. Specific founding year and detailed milestones require further research.
Core Business Areas
- Pharmaceutical Development: Focuses on developing novel ophthalmic therapies for various eye diseases and conditions.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Aims to commercialize approved ophthalmic products through strategic partnerships or in-house efforts.
Leadership and Structure
Information regarding Oculis Holding AG Ordinary shares's leadership team and organizational structure needs further research.
Top Products and Market Share
Key Offerings
- OCU400: A novel gene therapy candidate for retinitis pigmentosa (RP). Market share data unavailable. Competitors: Biogen, Spark Therapeutics.
- OCU200: A TNFu03b1 inhibitor in clinical development for dry eye disease (DED). Market share data unavailable. Competitors: AbbVie (Restasis, Xiidra), Novartis (Miebo).
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is characterized by increasing prevalence of eye diseases, technological advancements, and a growing aging population. It is a competitive landscape with established players and emerging biotech companies.
Positioning
Oculis Holding AG Ordinary shares positions itself as an innovator in ophthalmic therapies, focusing on unmet needs and utilizing gene therapy and other novel approaches. Its competitive advantage lies in its innovative pipeline.
Total Addressable Market (TAM)
The global ophthalmic market is projected to reach billions of dollars. Oculis is positioned to address specific segments within this market, particularly in gene therapy and dry eye disease, but specific penetration of the TAM requires revenue calculations
Upturn SWOT Analysis
Strengths
- Innovative pipeline of ophthalmic drug candidates
- Focus on unmet needs in eye care
- Potential for breakthrough therapies
- Strong intellectual property portfolio
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- High R&D expenses
- Small market capitalization, creating funding risk
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new ophthalmic indications
- Regulatory approvals for key drug candidates
- Increasing prevalence of eye diseases
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Generic erosion of existing ophthalmic drugs
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- BIIB
- ONCE
Competitive Landscape
Oculis is a relatively small player competing with larger pharmaceutical companies. Its advantages lie in its novel approaches and focus, but it faces challenges in terms of resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Discussing Oculis Holding AG Ordinary shares's growth trends over the past years requires further research and access to historical data.
Future Projections: Providing projections for Oculis Holding AG Ordinary shares's future growth based on analyst estimates requires further research and access to analysts.
Recent Initiatives: Highlighting recent strategic initiatives undertaken by Oculis Holding AG Ordinary shares requires further research.
Summary
Oculis Holding AG Ordinary shares is an innovative ophthalmic company with a promising pipeline, particularly in gene therapy. Its strengths lie in its focus on unmet needs, but it faces challenges typical of biotech firms, including clinical trial risks and competition. Successful development and commercialization of its products are critical for its long-term success and overall market position. The company has a small market share and is positioned in a niche market which requires substantial capital.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports (where available)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a financial professional. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oculis Holding AG Ordinary shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-02 | CEO & Director Dr. Riad Sherif M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://oculis.com |
Full time employees 49 | Website https://oculis.com | ||
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.